Drug Trial Radar · NCT06171048
Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
236
Planned (sponsor's estimate)
Start
Apr 30, 2024
Primary completion
Apr 30, 2025
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.
Conditions
- Healthy
Interventions
CM310Biological
CM310 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic: the maximum concentration (Cmax)Time frame: up to week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.